Membrane sterol depletion impairs miltefosine action in wild-type and miltefosine-resistant Leishmania donovani promastigotes

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 5, 2009, Pages

  Saint Pierre Chazalet, M ^a,b,c   Ben Brahim, M ^a,b   Le Moyec, L ^b,d   Bories, C ^a,b   Rakotomanga, M ^a,b   Loiseau, P M ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b CNRS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITÉ PARIS 13   (France)

Author keywords

Antileishmanial action; Chemotherapy; Drug resistance; Mechanism of action

Indexed keywords

BETA CYCLODEXTRIN; CHOLESTEROL; CHOLESTEROL OXIDASE; LIPID; MILTEFOSINE; STEROL; ANTIPROTOZOAL AGENT; DRUG DERIVATIVE; PHOSPHORYLCHOLINE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESISTANCE; DRUG STRUCTURE; LEISHMANIA DONOVANI; LIPID MONOLAYER; LIPID RAFT; NONHUMAN; PROMASTIGOTE; PROTON NUCLEAR MAGNETIC RESONANCE; WILD TYPE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; DRUG SENSITIVITY; LIPID METABOLISM; METABOLISM; MICROBIAL VIABILITY; MITOCHONDRION;

ANIMALS; ANTIPROTOZOAL AGENTS; CELL MEMBRANE; DRUG RESISTANCE; LEISHMANIA DONOVANI; LIPID METABOLISM; MICROBIAL VIABILITY; MITOCHONDRIA; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PARASITIC SENSITIVITY TESTS; PHOSPHORYLCHOLINE; STEROLS; TETRAZOLIUM SALTS; THIAZOLES;

EID: 73949091654     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp321     Document Type: Article

References (23)

1. Guerin PJ, Olliaro P, Sundar S et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002; 2: 494-501.
2. Desjeux P. Leishmaniasis. Nat Rev Microbiol 2004; 2: 692.
3. Croft SL, Seifert K, Yardley V. Current scenario of drug development for leismaniasis. Indian J Med Res 2006; 123: 399-410.
4. Eibl H, Unger C. Hexadecylphosphocholine: a new and selective antitumor drug. Cancer Treat Rev 1990; 17: 233-42.
5. Olliaro PL, Guerin PJ, Gerstl S et al. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 2005; 5: 763-74.
6. Perez-Victoria FJ, Gamarro F, Ouellette M et al. Functional cloning of the miltefosine transporter, a novel P-type phospholipid translocase from Leishmania involved in drug resistance. J Biol Chem 2003; 278: 49965-71.
7. Paris C, Loiseau PM, Bories C et al. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2004; 48: 852-9.
8. Verma NK, Dey CS. Possible mechanism of miltefosinemediated death of Leishmania donovani. Antimicrob Agents Chemother 2004; 48: 3010-5.
9. Rakotomanga M, Saint-Pierre-Chazalet M, Loiseau PM. Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug membrane interactions. Antimicrob Agents Chemother 2005; 49: 2677-86.
10. Luque-Ortega JR, Rivas L. Miltefosine (hexadecylphosphocholine) inhibits cytochrome C oxidase in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2007; 51: 1327-32.
11. Rakotomanga M, Loiseau PM, Saint-Pierre-Chazalet M. Hexadecylphosphocholine interaction with lipid monolayers. Biochim Biophys Acta 2004; 1661: 212-8.
12. Denny P, Field MC, Smith DF. GPI-anchored proteins and glycoconjugates segregate into lipid rafts in Kinetoplastida. FEBS Lett 2001; 491: 148-53.
13. Seifert K, Matu S, Perez-Victoria FJ et al. Characterization of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents 2003; 22: 380-7.
14. Blanc I, Saint-Pierre Chazalet M. Oligonucleotide delivery by cationic derivative of the polyene antibiotic amphotericin B: II: study of the interactions of the oligonucleotide/cationic vector complexes with lipid monolayers and unilamellar vesicles. Biochim Biophys Acta 2000; 1464: 309-21.
15. Heywang C, Saint-Pierre Chazalet M, Masson M et al. Incorporation of exogenous molecules inside mono- and bilayers of phospholipids: influence of the mode of preparation revealed by SERRS and surface studies. Langmuir 1996; 12: 6459-67.
16. de Certaines JD, Le Moyec L, Seguin F et al. Nuclear magnetic resonance spectroscopy of lipids in cancer. Current Organic Chem 2007; 11: 529-46.
17. Rakotomanga M, Blanc S, Gaudin K et al. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2007; 51: 1425-30.
18. Xu X, Bittmans R, Duportail G et al. Effect of the structure of natural sterols and sphingolipids on the formation of ordered sphingolipid/sterol domains (rafts). J BiolChem2001; 276: 33540-6.
19. Ahn KW, Sampson NS. Cholesterol-oxidase senses subtle changes in lipid bilayer structure. Biochemistry 2004; 43: 827-36.
20. Perez-Victoria FJ, Castanys S, Gamarro F. Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob Agents Chemother 2003; 47: 2397-403.
21. Menez C, Buyse M, Besnard M et al. Interaction between miltefosine and amphotericin B: consequences for their activities towards intestinal epithelial cells and Leishmania donovani promastigotes in vitro. Antimicrob Agents Chemother 2006; 50: 3793-800.
22. Mbongo N, Loiseau PM, Billion MA et al. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob Agents Chemother 1998; 42:352-7.
23. Mannechez A, Reungpatthanaphong P, de Certaines JD et al. Proton NMR visible mobile lipid signals in susceptible and multidrugresistant K562 cells are modulated by rafts. Cancer Cell Int 2005; 5: 2.